The market is experiencing significant growth driven by advancements in ureteroscopy and other cutting-edge technologies. These innovations are improving the effectiveness and safety of treatments, leading to better patient outcomes and greater adoption of minimally invasive techniques.
The development of virtual reality (VR) simulators for training urologists in ureteroscopy and other endourological procedures is enhancing proficiency and reducing the learning curve for new technologies.
Additionally, laser technology is widely used to break down kidney stones into smaller fragments that can be easily removed or passed naturally. Recent advancements include more powerful and precise laser systems capable of efficiently treating stones of varying sizes and compositions.
Moreover, advancements in extracorporeal shock wave lithotripsy (ESWL) technology have improved the efficiency and safety of non-invasive stone fragmentation. Modern ESWL devices offer better targeting and energy delivery, reducing the number of treatment sessions required.
Furthermore, innovations in percutaneous nephrolithotomy (PCNL) techniques, such as the use of smaller instruments (mini-PCNL) and improved imaging guidance, have made the procedure less invasive. Enhanced nephroscopes and stone retrieval tools contribute to more effective and safer stone removal. These advancements are expected to attract more patients and healthcare professionals, driving demand in the market.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The kidney stone management market was valued at around USD 2.6 billion in 2023 and is expected to reach around USD 4.1 billion by 2032, owing to the increasing prevalence and high recurrence rates of kidney stones.
The calcium oxalate segment of the market held a revenue of USD 1.9 billion in 2023 and will grow rapidly through 2032, owing to its high prevalence, caused by diets rich in calcium and oxalate-containing foods.
North America kidney stone management market accounted for USD 1.1 billion revenue in 2023 and is predicted to witness substantial growth through 2032, due to high disease prevalence, and advanced healthcare infrastructure.
Allengers Medical Systems Ltd, Becton, Dickinson and Company, Boston Scientific Corporation, Coloplast A/S, Cook Medical LLC, DirexGroup, Dornier MedTech, EDAP TMS S.A among others.